Objective. To evaluate the relationship between TGF signaling and endothelial lncRNA expression. Methods. Human umbilical vein endothelial cell (HUVECs) lncRNAs and mRNAs were profiled with the Arraystar Human lncRNA Expression Microarray V3.0 after 24 hours of exposure to TGF 1 (10 ng/mL). Results. Of the 30,584 lncRNAs screened, 2,051 were significantly upregulated and 2,393 were appreciably downregulated ( < 0.05) in response to TGF . In the same HUVEC samples, 2,148 of the 26,106 mRNAs screened were upregulated and 1,290 were downregulated. Of these 2,051 differentially expressed upregulated lncRNAs, MALAT1, which is known to be induced by TGF in endothelial cells, was the most (∼220-fold) upregulated lncRNA. Bioinformatics analyses indicated that the differentially expressed upregulated mRNAs are primarily enriched in hippo signaling, Wnt signaling, focal adhesion, neuroactive ligand-receptor interaction, and pathways in cancer. The most downregulated are notably involved in olfactory transduction, PI3-Akt signaling, Ras signaling, neuroactive ligand-receptor interaction, and apoptosis. Conclusions. This is the first lncRNA and mRNA transcriptome profile of TGF -mediated changes in human endothelial cells. These observations may reveal potential new targets of TGF in endothelial cells and novel therapeutic avenues for cardiovascular disease-associated endothelial dysfunction.
Introduction
Transforming growth factor-(TGF ) belongs to a large superfamily of linked proteins, comprising activins, bone morphogenetic proteins (BMPs), growth/differentiation factors, and anti-Müllerian hormone [1] that regulates proliferation, differentiation, migration, and survival in diverse cell populations depending on the cell type [2] . TGF 1, TGF 2, and TGF 3 are the most common of the isoforms that are involved in these functions [3] . Prior to binding to its specific type I and type II serine/threonine kinase receptors, the latent form of TGF is activated by proteases or thrombospondin. It is well documented that TGF signaling involves one TGF type II receptor and two distinct TGF type I receptors, that is, the endothelium limited activin receptor-like kinase (ALK1) and the largely expressed ALK5. Activated ALK5 after ligand binding transduces signals from the membrane to the nucleus via phosphorylation of a specific subset of intracellular effectors termed Smads [3, 4] . While ALK1 activation phosphorylates Smad1, Smad5, and Smad8, ALK5 mediates Smad2 and Smad3 phosphorylation. The heteromeric complex of phosphorylated Smad2/Smad3 with 2 International Journal of Vascular Medicine Smad4 then translocates to the nucleus, where, together with various transcriptional regulators, it leads to the transcription of a wide array of target genes [5, 6] .
Several in vivo studies have shown that interfering with the components of the TGF 1 signaling pathway, including TGF 1 [7] , TGF R-II [8] , ALK5 [9] , endoglin [10] , ALK1 [11] , or Smad5 [12] , through gene targeting results in extreme vascular anomalies in mice as illustrated by enlarged vessels and defective differentiation of smooth muscle cells. Depending on the experimental conditions and animal models, TGF 1 has been also shown to function as an inhibitor or a promoter of angiogenesis [13, 14] . Given its multifunctional role in cellular processes, disturbed TGF 1 signaling is notably evident in various human disorders [15, 16] . Evidence for how TGF 1 contributes to the advancement of tumors is conflicting and appears to be dependent on the developmental stage of the tumor. TGF 1 acts as an inhibitor of proliferation during the initial stages of tumor development. However, upon attenuation of this antiproliferative signal, tumor cells often secrete great amounts of TGF 1 which promote cell invasion, epithelial-to-mesenchymal transition (EMT) metastasis, and angiogenesis which collectively establish a growth-supportive tumor microenvironment [4, 17, 18] .
In recent years, the long noncoding RNAs (lncRNAs) have emerged as regulators and potential therapeutic targets for a wide variety of physiological and pathological processes [19, 20] . Typically, lncRNAs are transcripts greater than 200 nucleotides that lack an open reading frame and proteincoding ability. Although the lncRNAs are not as well conserved as protein-coding genes and microRNA, increasing evidence suggests that lncRNAs are involved in a variety of cellular functions like proliferation, survival, migration, invasion, angiogenesis, and differentiation and could serve as alternative therapeutic targets [21] [22] [23] [24] [25] [26] . MALAT1 (metastasis associated lung adenocarcinoma transcript 1), which is amongst the most abundant and highly conserved lncRNAs, exhibits specific nuclear localization, developmental regulation, and dysregulation in cancer, all of which are indicative of its critical role in multiple biological processes [27] . MALAT1 is an important mediator of TGF signaling and may represent a promising therapeutic option for suppressing bladder cancer progression [28] . MALAT1 is highly expressed in endothelial cells and loss of MALAT1 tips the balance from a proliferative to a migratory endothelial cell phenotype in vitro and reduces vascular growth in vivo [29] .
To date, the nuances underlying the transcriptional regulation of lncRNAs by TGF 1 in endothelial cells remain unexplored. The goal of the current study was to profile the changes in lncRNA expression in association with TGF 1 signaling in endothelial cells that may provide insights into regulation of endothelial function by TGF 1-associated lncRNAs. This approach also allowed us to identify novel lncRNA targets and associated pathways of TGF 1 in endothelial cells.
Materials and Methods

Cell Culture.
Human umbilical vein endothelial cells (HUVECs, Lonza) were cultured in endothelial cell growth medium-2 (EGM6-2 Bulletkit6; Lonza) supplemented with growth factors, serum, and antibiotics at 37 ∘ C in humidified 5% CO 2 . Confluent HUVECs were split into 6 and maintained in 6-well plates for 24 hours in the absence (3 plates) or presence (3 plates) of recombinant TGF 1 (10 ng/mL; R&D Systems).
Microarray Profiling.
Total RNA was isolated using TRIzol6 (Invitrogen) reagent and quantified with the NanoDrop ND-1000 spectrophotometer. RNA integrity was confirmed by standard denaturing agarose gel electrophoresis. The expression profile of 30,584 human lncRNAs and 26,106 protein-coding transcripts was conducted with the Arraystar Human LncRNA Microarray V3.0. Sample labeling and array hybridization were performed on the Agilent Array platform. Briefly, total RNA from each sample was amplified and transcribed into fluorescent cRNA (Arraystar Flash RNA Labeling Kit, Arraystar) before 1 g of each labeled cRNA was hybridized onto the microarray slide. The hybridized arrays were washed, fixed, and scanned with the Agilent DNA Microarray Scanner (Product # G2505C). The acquired array images were analyzed with the Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing were performed with the GeneSpring GX v11.5.1 software package (Agilent Technologies). values for the differentially expressed genes were determined with the -test and adjusted for multiple testing with the Benjamini Hochberg method to minimize the false discovery rate. Volcano plot filtering, set at a threshold of ≥2.0-fold, was used to screen for lncRNAs and mRNAs that exhibited significantly different ( < 0.05; unpaired -test) expression levels in the two study groups. Pathway analysis was based on the current Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Gene ontology (GO) analysis was performed with the topGO package of bioconductor system. Figure 1) .
Results
Quality Assessment of LncRNAs and mRNAs
Scatter plots provided a profile of HUVEC lncRNAs (Figure 1(a) ) and mRNAs ( Figure 1(b) ) that were upregulated, downregulated, or unaffected by exposure to TGF 1 treatment. Overall, the average fold-changes of lncRNAs and mRNAs differentially expressed under the study conditions were similar (Figure 1(c) ). Subsequent volcano plot filtering uncovered 2,051 significantly upregulated and 2,393 significantly downregulated lncRNAs in HUVECs cultured with TGF 1 relative to control samples ( Figure 1(d) Table 1 lists the 10 most up-/downregulated lncRNAs depending on the fold-change expression. TGF 1 treatment associated changes at the transcript level were also noted amongst 3,436 mRNAs with 2,148 upregulated and 1,290 downregulated ( Figure 1 (e); < 0.05; Supplement Tables C  and D) .
LncRNA Chromosomal Distribution and Subtype Analysis.
Supplementary Figure 2 shows the dendrograms generated for hierarchical analysis of clustered lncRNAs and mRNAs that were differentially expressed in HUVECs cultured in media with TGF 1 in comparison to controls. Although lncRNAs modulated by TGF 1 treatment were abundant and found on every human chromosome, most were located on chromosomes 1, 2, and 17 ( Figure 2(a) ). Further probing revealed that while these differentially expressed lncRNAs are expressed along the entire length of the chromosomes, there is a notable clustering of lncRNAs (Figure 2(b) ). LncRNA subgroup analysis, which helps identify the functional relationship between lncRNAs and their associated protein-coding genes, demonstrated that the majority (∼50%) of lncRNAs were intergenic in origin followed by intron and natural antisense lncRNAs (Figure 2(c) ). We also identified bidirectional, exon sense-overlapping, and intron sense-overlapping lncRNAs (Figure 2(c) ).
LncRNAs and Associated Protein-Coding Transcripts.
We conducted additional profiling to gather insight into differentially expressed lncRNAs and associated proteincoding transcripts. The fold-change calculated for the top 10 highly up-/downregulated lncRNA with known associated protein-coding genes is summarized in Figure 3 . Interestingly, MALAT1, which is highly expressed in endothelial cells [29] and is an important mediator of TGF signaling [28] , was the most upregulated lncRNA after TGF -stimulation ( Figure 3 ). The protein-coding genes LTBP3, KCNK7, and TGD3, which are adjacent to MALAT1 on chromosome 15 [27] , were also significantly upregulated ( Figure 3 ). Of note, 9 of the 20 lncRNAs demonstrated a direct correlation in foldchange with its associated mRNA, whereas the remaining 11 displayed an inverse correlation. Inverse relation was mainly observed for the downregulated (9 out of 10) lncRNAs ( Figure 3 ).
Bioinformatics Analyses.
Pathway analysis with the current KEGG database yielded several pertinent findings (Tables 2 and 3 ). In brief, mRNAs upregulated in response to TGF 1 treatment are involved in hippo signaling, Wnt signaling, focal adhesion, neuroactive ligand-receptor interaction, and cancer-associated pathways ( Table 2 ). The most downregulated mRNAs are notably involved in olfactory transduction, PI3K-Akt signaling, Ras signaling, neuroactive ligand-receptor interaction, and apoptosis (Table 3) . Bioinformatics GO analyses grouped the differentially expressed mRNAs under the following three categories: biological processes, cellular component, and molecular function. GO terms most broadly associated with upregulated mRNAs were biological function, protein binding, and signalling (Table 4) . GO terms associated with downregulated mRNA were mainly enriched in cell, response to stimulus, and multicellular organism process (Table 4) . 
Discussion
The underlying dogma of molecular biology for the last few decades has been that the purpose of RNA is to direct the assembly of proteins from amino acids through translation. A few exceptions to this paradigm are ribosomal RNA and transfer RNA which are functional RNA macromolecules that do not encode protein. A large proportion (>80%) of the human genome is transcribed, but protein-coding transcripts account for only ∼2% of whole transcriptome [30] . This suggests that the majority of the genomes are transcribed as non-protein-coding RNAs. Among noncoding RNAs, a novel class of noncoding RNAs, which stretch more than 200 nucleotides and are termed long noncoding RNAs (lncRNAs), has recently emerged [31] . Evidence to date suggests that the mechanisms underlying gene regulation by lncRNAs are highly complex and involve both inhibition and activation of gene expression [32] . The growing appreciation of the multitude of mechanisms, functions, and types of lncRNAs has set off a research tsunami to clarify the involvement of lncRNAs in the etiology of disease states. Although there have been reports demonstrating that lncRNAs are dysregulated in several human diseases, it has yet to be confirmed that these molecules can [33] . At present, the strongest association lies with cancer [34] where altered expression of several lncRNAs has been documented [35, 36] . LncRNA PCAT-1 which is a target of histone-modifying PRC2 complex bearing both oncogenic and tumor-suppressive features was found to promote cell proliferation [37] ; antisense noncoding RNA in the INK4 locus (ANRIL; also known as CDKN2BAS) is upregulated in prostate cancer and implicated in tumor suppression [38] ; HOTAIR upregulation is associated with poor prognosis in pancreatic [39] , colorectal [40] , liver [41] , gastrointestinal [42] , and breast [43] cancers and likely also contributes to increased metastasis [43] of these cancer types. MALAT1 was one of the first lncRNAs to be implicated in cancer and a series of studies have established its potential importance as a biomarker and potential therapeutic target for cancer metastasis [44] . Increased expression of MALAT1 is observed in lung, breast, colon, cervical, colorectal, ovarian, gastric, and other cancer types [44] . Mechanistically, MALAT1 affects the transcriptional and posttranscriptional regulation of cytoskeletal and extracellular matrix genes [45] . A similar function has been postulated for lincRNA-p21 (named for its vicinity to the CDKN1A/p21 locus) in cancer, which functions as a repressor in p53-dependent transcriptional responses particularly on genes regulating apoptosis, possibly by directing the recruitment of hnRNP-K to its genomic targets [36] . Although the biological significance of lncRNAs has perhaps been most extensively investigated in cancers, it is noteworthy that several lines of evidence purport a role for lncRNAs in nonneoplastic conditions such as development [46] and cardiovascular diseases (CVDs). The first evidence suggestive of a lncRNA-CVD association stemmed from genome-wide association studies that independently identified a susceptibility locus of coronary artery disease (CAD) on human chromosome 9p21 [47, 48] . This locus is adjacent to the last exon of ANRIL. That the proteincoding genes cyclin-dependent kinase inhibitors 2A and 2B (CDKN2A and CDKN2B, resp.) lie >100 kb from associated single nucleotide polymorphisms (SNPs) suggested to the investigators that SNPs in ANRIL increases the susceptibility to CAD and other vascular diseases [49] [50] [51] . The lncRNAs MALAT1, MEG3, and TUG1 are highly expressed in endothelial cells [29] and are induced under low oxygen conditions in vitro in endothelial cells [29] ; MALAT1 expression is similarly affected in vivo in ischemic limbs [29] . Inhibition of MALAT1 promoted RNA degradation in an RNase Hdependent mechanism and promoted migration of tip cells but blocked proliferation of subsequent stalk cells leading to an abnormal tube formation in vitro [29] . Genetic deletion or pharmacological inhibition of MALAT1 impaired vascularization in vivo [29] . Bioinformatics analysis of MALAT1-regulated genes revealed that MALAT1 supports the proliferation of endothelial cells through its cell cycle regulatory effects [29, 52] . Notably, the enhanced levels of MALAT1 observed in patients with ischemia [29] are consistent with the upregulation of MALAT1 previously described in in vitro and in vivo models [29] .
Deep sequencing studies have identified lncRNAs in human coronary aortic smooth muscle cells (SMCs) by comparing their expression profiles to those of HUVECs [53] . After screening 31 lncRNAs, 1 lncRNA, namely, smooth muscle and endothelial cell-enriched migration/differentiationassociated long noncoding RNA (SENCR), was studied in detail, which is highly expressed in endothelial cells, SMCs, and aortic tissue [53] . In SMCs, loss of SENCR significantly enhanced SMC migration and reduced expressions of SMC contractile markers [53] . Another study evaluating the regulation and function of lncRNAs in human aortic valve cells demonstrated that cyclic stretch reduced the expression of the lncRNA HOTAIR and also that loss of HOTAIR elevated expressions of calcification-related genes, indicating its role in aortic valve calcification [54] . In the heart, Fendrr (Fetal-lethal noncoding developmental regulatory RNA) is an excellent example for the role of lncRNAs in cardiac development as intraventricular septal heart defects were observed embryonically in Fendrr-deficient mice [55] .
Role of other lncRNAs in CVDs is demonstrated by lncRNA MIAT, which is associated with increased risk of myocardial infarction [56] ; lncRNA ANRIL is associated with increased risk to coronary heart disease [57] ; lncRNA DBE-T localizes to the facioscapulohumeral muscular dystrophy (FSHD) locus [58] ; and a novel lncRNA is identified in association with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) [59] . Furthermore, vascular lincRNA-p21 represses proliferation and induces apoptosis in vitro and in vivo in vascular smooth muscle cells [60] . Loss of endogenous lincRNA-p21 exacerbates neointima formation in injured carotid arteries in the carotid artery injury model [60] . This finding is highly relevant because it implicates lncRNAs to CVDs and indicates that lincRNA-p21 may be a novel therapeutic approach to treat human atherosclerosis and related CVDs [60] .
TGF belongs to a large superfamily of related polypeptides and is involved in diverse biological processes, such as cell proliferation, migration, differentiation, survival, and cell-cell and cell-matrix interaction [1] . TGF plays a crucial role in the development of the cardiovascular system, affecting functions of both endothelial and periendothelial cells [61] . TGF -associated signaling is a key player in metazoan biology, and its dysregulation can result in either developmental defects or other pathologies like tumor development [15] . Consequently, the output of a TGF -response is known to be highly context-dependent in development, across different tissues, as well as in cancer syndromes [15] . Dysregulated TGF -associated signaling is linked to human hereditary hemorrhagic telangiectasia (HHT) type II [62] and HHT type I [63] . HHT patients present with dilated blood vessels with thin walls and exhibit abnormal arteriovenous fusion and shunting. Studies have revealed that the dysregulation of the TGF signaling pathway results in severe vascular abnormalities in mice models of vasculogenesis [7] [8] [9] [10] [11] [12] . The TGF -pathway is also responsible for the endothelial to mesenchymal transition (EndMT), a process by which endothelial cells acquire mesenchymal gene signatures to become more motile and invasive [18, 64] . EndMT plays an important role in the developmental process, as well as in the development of organ fibrosis [18, 64] . TGF signaling is thus essential for vascular development and maturation, but International Journal of Vascular Medicine 9 the mechanisms of transcriptional regulation of this signaling have not been clearly defined.
To determine targets of TGF in endothelial cells, we performed lncRNA and mRNA microarray analysis on total RNA isolated from TGF -stimulated HUVECs. This approach allowed us to identify novel target genes of TGF and provided insights into the regulation of different lncRNAs and mRNAs by TGF in endothelial cells. Of the 30,584 lncRNAs screened, 2051 were significantly upregulated and 2393 were appreciably downregulated ( < 0.05) in response to TGF 1. In the same HUVEC samples, 2148 of the 26,106 mRNAs screened were upregulated and 1290 were downregulated. Interestingly, of the 2051 differentially expressed upregulated lncRNAs, MALAT1, which is highly expressed in endothelial cells [29] and is an important mediator of TGF signaling [28] , was the most (∼220-fold) upregulated lncRNA after TGF -stimulation in endothelial cells (Figure 3 ). The protein-coding genes LTBP3, KCNK7 and TGD3, which are adjacent to MALAT1 on chromosome 15 [27] , were also significantly upregulated in our mRNA array data ( Figure 3 ). Our data shows that 9 of the 20 lncRNAs demonstrated a direct correlation in fold-change with its associated mRNA, whereas the remaining 11 displayed an inverse correlation, which was mainly observed for the downregulated (9 out of 10) lncRNAs (Figure 3) .
Pathway analysis revealed that lncRNAs upregulated in response to TGF 1 treatment are involved in hippo signaling, Wnt signaling, focal adhesion, neuroactive ligand-receptor interaction, and pathways specific to cancer ( Table 2 ). The most downregulated lncRNAs are notably involved in olfactory transduction, PI3-Akt signaling, Ras signaling, neuroactive ligand-receptor interaction, and apoptosis (Table 3) . The proposed common pathophysiological basis between cancer and CVDs [65] [66] [67] [68] is strengthened by the role of lncRNAs such as MALAT1 [29, 44] , p21 [49, 60] , ANRIL [38, 49, 60] , and HOTAIR [39, 54] in the development of cancer as well as in CVDs. Accordingly, differentially expressed lncRNA MALAT1 and pathway analysis of our data also demonstrate the common pathways indicating similar pathophysiological basis between cancer and CVDs ( Table 2) . Results of bioinformatics GO analysis, as described in Table 4 , grouped the differentially expressed mRNAs under the following three categories: biological processes, cellular component, and molecular function. GO terms most broadly associated with upregulated mRNAs were biological function, protein binding, and signalling (Table 4) . GO terms associated with downregulated mRNA were mainly enriched in cell, response to stimulus, and multicellular organism process (Table 4) . This is the first lncRNA and mRNA transcriptome profile of TGF -mediated changes in human endothelial cells. These observations may reveal some new targets of TGF in endothelial cells and CVDassociated endothelial dysfunction. Further investigations of novel genes identified by this study will provide new clues concerning the mechanisms of vascular development by TGF and contribute to therapeutic approaches to vascular diseases as well as treating cancer.
Interest in the contribution of LncRNAs to human health and disease is booming, but much effort is required to determine the full contribution and the mechanisms by which lncRNAs exert their effects. Efforts such as the Encyclopedia of DNA Elements (ENCODE) project aiming to identify all functional elements in the human genome are making major progress [69] ; methods based on secondgeneration RNA sequencing are expected to provide a more detailed picture of the whole human lncRNA transcriptome. The lack of a complete understanding of functional motifs, low expression levels of some lncRNAs, and the need for a better definition of lncRNAs regulatory regions make the characterization of lncRNA challenging. One of the most important challenges is to identify all encoded functional lncRNAs, and emerging genomic, epigenomic, and bioinformatics approaches will be crucial in this context. However, the restricted spatiotemporal expression of many lncRNAs, as well as the binding of transcription factors to noncoding loci, could be used as evidence of functionality. The poor conservation and the fact that most lncRNAs are expressed as various transcript variants challenges the identification of specific biological functions and mechanisms of action. Often, identification of lncRNA sequences from published studies is not trivial and chromosomal localization is not provided. To avoid confusion and to facilitate the use and reproduction of the data, more details should be provided (e.g., chromosomal localization and deposition of the identified transcript into publicly available databases), which we have implemented in our data presentation. Furthermore, the mechanism of action has only been identified for a few lncRNAs.
Despite these challenges, in a short period, lncRNAs have become a major new class of transcripts that potentially comprise a major component of the genome's information content in comparison to the abundance and complexity to the proteome. LncRNAs have already been reported in a wide range of human diseases suggesting their crucial activity in human health and disease [33] . In addition, therapeutic strategies that target endogenous mRNA molecules could also be adapted to target lncRNAs, whose expression is dysregulated in human CVDs. These observations suggest that lncRNAs represent a novel and versatile class of molecules that are centrally important to the modulation of different CVD conditions and could potentially be utilized for developing novel diagnostic and therapeutic approaches to cure CVDs. With respect to the predictive value of the measured lncRNAs in human diseases, the increased MALAT1 expression levels in ischemic patients and the initial levels of ANRIL and KCNQ1OT1 in peripheral blood mononuclear cells in patients with left ventricular dysfunction at 4-month follow-up [70] suggest that lncRNAs might also be useful as indicators for CVDs. These important developments are expected in this area and exciting times lie ahead of us.
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